The FDA rejected oral treprostinil, a prostacyclin vasodilator, for the second time for the treatment of pulmonary arterial hypertension. The Agency issued a complete response letter to United Therapeutics explaining the rejection. The drug is on the market in injectable and inhalable forms.

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Pulmonary Hypertension and Venous Thromboembolism, Vascular Medicine, Lipid Metabolism, Pulmonary Hypertension, Hypertension

Keywords: Epoprostenol, Vasodilator Agents, Hypertension, Pulmonary

< Back to Listings